133 related articles for article (PubMed ID: 33340712)
21. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Raj GV; Partin AW; Polascik TJ
Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
[TBL] [Abstract][Full Text] [Related]
22. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.
Spratt DE; Dai DLY; Den RB; Troncoso P; Yousefi K; Ross AE; Schaeffer EM; Haddad Z; Davicioni E; Mehra R; Morgan TM; Rayford W; Abdollah F; Trabulsi E; Achim M; Tapia ELN; Guerrero M; Karnes RJ; Dicker AP; Hurwitz MA; Nguyen PL; Feng FFY; Freedland SJ; Davis JW
Eur Urol; 2018 Jul; 74(1):107-114. PubMed ID: 29233664
[TBL] [Abstract][Full Text] [Related]
23. Benign prostatic glands at surgical margins of radical prostatectomy specimens: frequency and associated risk factors.
Shah R; Bassily N; Wei J; Mucci NR; Montie JE; Sanda MG; Rubin MA
Urology; 2000 Nov; 56(5):721-5. PubMed ID: 11068287
[TBL] [Abstract][Full Text] [Related]
24. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer.
Taylor N; Kelly JF; Kuban DA; Babaian RJ; Pisters LL; Pollack A
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):755-63. PubMed ID: 12788182
[TBL] [Abstract][Full Text] [Related]
26. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?
Choo R; Hruby G; Hong J; Hong E; DeBoer G; Danjoux C; Morton G; Klotz L; Bhak E; Flavin A
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):674-80. PubMed ID: 11849789
[TBL] [Abstract][Full Text] [Related]
27. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
28. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
Caster JM; Falchook AD; Hendrix LH; Chen RC
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
[TBL] [Abstract][Full Text] [Related]
29. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
Gandaglia G; Boorjian SA; Parker WP; Zaffuto E; Fossati N; Bandini M; Dell'Oglio P; Suardi N; Montorsi F; Karnes RJ; Briganti A
Eur Urol; 2017 Dec; 72(6):910-917. PubMed ID: 28622831
[TBL] [Abstract][Full Text] [Related]
30. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment.
McCarthy JF; Catalona WJ; Hudson MA
J Urol; 1994 Jun; 151(6):1575-8. PubMed ID: 7514691
[TBL] [Abstract][Full Text] [Related]
31. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
[TBL] [Abstract][Full Text] [Related]
33. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ
J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793
[TBL] [Abstract][Full Text] [Related]
34. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.
Freedland SJ; Partin AW; Epstein JI; Walsh PC
Cancer; 2004 Apr; 100(8):1646-9. PubMed ID: 15073852
[TBL] [Abstract][Full Text] [Related]
35. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy.
Goluboff ET; Heitjan DF; DeVries GM; Katz AE; Benson MC; Olsson CA
J Urol; 1997 Nov; 158(5):1876-8; discussion 1878-9. PubMed ID: 9334621
[TBL] [Abstract][Full Text] [Related]
36. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
Malik RD; Goldberg JD; Hochman T; Lepor H
Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
[TBL] [Abstract][Full Text] [Related]
37. Population-based analysis of salvage radical prostatectomy with examination of factors associated with adverse perioperative outcomes.
Pearce SM; Richards KA; Patel SG; Pariser JJ; Eggener SE
Urol Oncol; 2015 Apr; 33(4):163.e1-6. PubMed ID: 25708953
[TBL] [Abstract][Full Text] [Related]
38. The use of early postoperative prostate-specific antigen to stratify risk in patients with positive surgical margins after radical prostatectomy.
Vesely S; Jarolim L; Duskova K; Schmidt M; Dusek P; Babjuk M
BMC Urol; 2014 Oct; 14():79. PubMed ID: 25277310
[TBL] [Abstract][Full Text] [Related]
39. Influence of Geography on Prostate Cancer Treatment.
Tang C; Lei X; Smith GL; Pan HY; Hoffman KE; Kumar R; Chapin BF; Shih YT; Frank SJ; Smith BD
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1286-1295. PubMed ID: 33316361
[TBL] [Abstract][Full Text] [Related]
40. Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen.
Greenberg SA; Washington SL; Lonergan PE; Cowan JE; Baskin AS; Nguyen HG; Odisho AY; Simko JP; Carroll PR
J Urol; 2021 Sep; 206(3):706-714. PubMed ID: 33905262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
